SQUAMOUS CELL CARCINOMA OF HEAD AND NECK

This early-phase study tested a new drug called TPST-1495, alone or with another drug (pembrolizumab), in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancer) that had stopped responding to standard treatments. The main goal was to find the safest…

This study tested whether adding the drug setanaxib to the standard immunotherapy pembrolizumab can better shrink tumors in people with advanced head and neck cancer that has returned or spread. 55 adults whose cancer could not be removed by surgery took part. The main goal was t…

This study tested a combination of three drugs (camrelizumab, cetuximab, and chemotherapy) as a first treatment for people with head and neck cancer that had come back or spread. 41 participants received the drug combo to see how many would have their tumors shrink or disappear. …

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in people with head and neck cancer that returned or spread and got worse after standard chemotherapy and immunotherapy. The goal was to see if this combo helps people live longer compared to standard che…

This study tested whether adding a new drug (tiragolumab) to a standard immunotherapy (atezolizumab) helps shrink tumors in people with advanced head and neck cancer that has spread or come back. 123 adults with a specific type of head and neck cancer (PD-L1 positive) who had not…

This study tested a new drug called ozuriftamab vedotin in 42 people with head and neck cancer that had come back or spread. The goal was to see if the drug could shrink tumors and how safe it was. Researchers measured how many patients responded to treatment and tracked side eff…

This early-phase study tested a new drug (TAK-676) combined with pembrolizumab after radiation in 34 adults with lung, triple-negative breast, or head/neck cancers that had stopped responding to standard treatments. The main goals were to check safety, side effects, and find the …

This early-stage study tested a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, or stomach cancers). The main goal was to check for side effects and see how the body processes the drug. It was not designed to measure if t…

This early-phase study looked at whether a plant protein called MASL can target a receptor (podoplanin) found on oral cancer cells. Researchers tested cells from 18 people with oral cancer or precancerous lesions to see if MASL could slow growth. The goal was to understand how th…

This study looked at how people with a serious type of skin cancer on the head or neck feel about their treatment decisions, quality of life, and satisfaction with care. Researchers asked 78 patients to fill out questionnaires about their health, worries, and how supported they f…